Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $230 from $205 and keeps a Buy rating on the shares. The company delivered a clean Q3 beat and raise result fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note. The increase in FY25 revenue guidance signals the management’s confidence in broad portfolio momentum going forward, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: